Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natus set to grow neurology offering with NeuroCom buy

This article was originally published in Clinica

Executive Summary

Natus Medical is set to expand its neurology product line with the purchase of NeuroCom International, a firm specialising in the development of computerised systems for the assessment and rehabilitation of mobility disorders. Natus (San Carlos, California) expects to close the $18m cash deal in early October 2008 and, in doing so, affirm its position as the “market leader in neurology”. The firm, which also has products for sleep disorders, newborn care, hearing impairment and epilepsy, also said the deal would be immediately accretive to its earnings. Clackamas, Oregon-based NeuroCom has developed Computerized Dynamic Posturography (CDP) technology, which is designed to aid patients with balance disorders. It recorded revenues of $11.3m in the twelve months ended June 30 2008.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel